iBio IBIO
NASDAQ IBIO
$1.12 +0.01 (+0.90%)
At close: Oct 2, 2026 · 4:00 PM EDT

iBio (IBIO) Other Accumulated Expenses (2011 - 2026)

Updated

iBio's Other Accumulated Expenses was $205,000 in fiscal Q4 2026 (quarter ended Jun 30, 2026), up 84.7% from $111,000 a year earlier.

Analysis

iBio (IBIO) Other Accumulated Expenses (2011 - 2026) Analysis & Trends

From fiscal Q4 2011 onward, iBio has reported Other Accumulated Expenses for 9 quarters.

  • Other Accumulated Expenses shows a five-year compound annual growth rate of 8.6% (FY2021 to FY2026).
  • In earlier fiscal years, Other Accumulated Expenses was $111,000 in FY2025 (-75.9%), $460,000 in FY2024 (-76.3%), $1.94 million in FY2023 (+747.6%) and $229,000 in FY2022 (+68.4%).
  • The fiscal Q4 2026 figure marks the highest quarterly Other Accumulated Expenses since fiscal Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 iBio 116.55 Mn 116.55 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 205,000.00
Jun 30, 2025 111,000.00
Jun 30, 2024 460,000.00
Jun 30, 2023 1.94 Mn
Jun 30, 2022 229,000.00
Jun 30, 2021 136,000.00
Jun 30, 2020 167,000.00
Jun 30, 2012 59,931.00
Jun 30, 2011 56,059.00
API Access

iBio Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=IBIO&period=max&api_key=YOUR_API_KEY